Using small molecules to enhance cancer immunotherapy through a new cell death mechanism
Small-molecule exploitation of ZBP1-driven nuclear necroptosis for cancer immunotherapy
This study is exploring a new way to boost cancer treatment by using special molecules to help your immune system recognize and fight tumors that usually resist current therapies, aiming to improve outcomes for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11035222 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve cancer immunotherapy by activating a specific type of cell death called necroptosis, which can enhance the immune response against tumors. The researchers aim to use small molecules that trigger necroptosis in cancer cells, making them more visible to the immune system. By focusing on tumors that are typically resistant to existing therapies, this approach seeks to create a more immunogenic tumor microenvironment, potentially leading to better treatment outcomes for patients. The study builds on previous findings related to viral infections and their ability to stimulate immune responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with 'cold' tumors that have shown resistance to current immunotherapy treatments.
Not a fit: Patients with tumors that are already responsive to existing immunotherapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments for patients whose tumors currently do not respond to standard immunotherapies.
How similar studies have performed: While the approach of using small molecules to activate necroptosis is innovative, similar strategies targeting immune responses in cancer have shown promise in other studies.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Balachandran, Siddharth — Research Inst of Fox Chase Can Ctr
- Study coordinator: Balachandran, Siddharth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.